Tiny probe aims to give Real-Time cancer answers for lung spots

NCT ID NCT07827326

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 18, 2026 · Last updated Sep 21, 2026 · Updated 1 time

Summary

Researchers are testing a needle-based confocal laser endomicroscopy (nCLE) probe to see if it can tell malignant from benign peripheral pulmonary lesions during a bronchoscopy. One hundred adults with a lung lesion seen on CT will receive a fluorescent dye and then have the tiny probe placed against the lesion to capture microscopic images. Doctors will compare those images to the final diagnosis from tissue samples or follow-up scans to measure how accurate the probe is.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
needle-based confocal laser endomicroscopy with fluorescein dye
What this could lead to
If it works, doctors could get an immediate answer about whether a lung spot is cancer during a bronchoscopy, possibly reducing the need for repeat procedures or waiting days for lab results.
What could go wrong
This is a diagnostic accuracy study, not a treatment trial, and it may show the microscope images are not reliable enough to replace standard tissue biopsy. The procedure also requires intravenous dye and inserting a probe deep into the lung, which carries small risks of bleeding or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of adults aged 18 years or older with peripheral pulmonary lesions detected on chest computed tomography who are referred to the respiratory endoscopy units of three participating tertiary hospitals in China for clinically indicated diagnostic bronchoscopy and tissue sampling. Eligible patients will be prospectively screened and invited to participate. Participants must be willing to undergo radial probe endobronchial ultrasound localization and needle-based confocal laser endomicroscopy and must provide written informed consent. Patients with lesions ultimately diagnosed as either malignant or benign will be included.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older. * A peripheral pulmonary lesion identified on chest CT. * Bronchoscopic biopsy considered clinically necessary by the treating physician to establish a pathologic diagnosis. * Willingness to undergo r-EBUS and nCLE examinations. * Voluntary participation with written informed consent. Exclusion Criteria: * A contraindication to bronchoscopy, including severe cardiopulmonary disease,coagulation disorder, failure to discontinue anticoagulant therapy or anticoagulant medication for at least 5 days before the procedure, poor tolerance of anesthesia,psychiatric illness, or severe neurosis. * Pregnancy or breastfeeding. * Known allergy to fluorescein sodium. * Coagulation disorder. * A known allergic disorder, history of asthma, hepatic failure, renal failure, or another contraindication to fluorescein sodium injection. * Continued use of a systemic beta-blocker on the day of the procedure, or inability to discontinue the beta-blocker safely as assessed by the investigator and anesthesiologist. * Inability to cooperate with the study for any reason, or any other condition that the investigator considers unsuitable for enrollment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Peripheral pulmonary lesions are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Anhui Chest Hospital

    Hefei, Hefei, 230022, China

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, 200030, China

  • The First Affiliated Hospital of Ningbo University

    Zhejiang, Ningbo, 315000, China